

ASX Release

TALI APPOINTS NEW COMPANY SECRETARY

The Board of Directors of TALi Digital Limited (TALi) (ASX: TD1) is pleased to announce the appointment of Mr Tim Luscombe as Company Secretary for TALi, effective 5 December 2022. Tim replaces Queensland based Stephen Denaro, who has been the Company Secretary for TALi since 2019.

Tim is a Director at Bio101 Financial Advisory (Bio101), a financial services firm providing outsourced CFO, tax and company secretarial solutions to the Healthcare sector. His appointment as Company Secretary compliments his existing responsibilities as Chief Financial Officer equivalent, a role Bio101 has fulfilled since 2020. Tim holds a Bachelor of Commerce from the University of Melbourne and a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.

This appointment follows the resignation of Mr Stephen Denaro as Company Secretary, effective 5 December 2022. The Board would like to thank Stephen for his dedication and service since his appointment to the role of Company Secretary in February 2019 and wish him every success in his future endeavours.

Release authorised by:

The Board of TALi Digital Limited

CONTACT**Corporate**

Mark Simari
Chair
TALi Digital 1300 082 013
investors@talidigital.com

Investors

Mary Beth Brinson
CEO
TALi Digital 1300 082 013
investors@talidigital.com

About TALi Digital

TALi Digital Limited (ASX: TD1) is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy, placing TALi at the forefront of improving early intervention for childhood attention and concentration performance. We believe in healthy, happier minds – our vision is to deliver a personalised digital experience to enhance cognitive care.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). Learn more at talidigital.com.